Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2019 09:26 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals to Present Preclinical Data at the 29th Annual Symposium of the International Cannabinoid Research Society

SAN DIEGO, CA, June 19, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, will present preclinical data...
May 15, 2019 08:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals to Participate at the Neurotech Investing & Partnering Conference

SAN DIEGO, CA, May 15, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, will participate in a panel...
April 17, 2019 08:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals Receives U.S. Drug Enforcement Administration Determination that the Active Ingredient in its Lead Product Candidate is not a Controlled Substance

Development of EHP-101, a clinical-stage cannabidiol (CBD) derivative, simplified by DEA determination SAN DIEGO, CA, April 17, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc....
March 21, 2019 07:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals’ Cannabinoid-Derived Drug Candidate, EHP-102, Shows Potential Disease-Modifying Activity in Huntington’s Disease Models

SAN DIEGO, CA, March 21, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that newly...
March 19, 2019 13:14 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals’ Cannabinoid-Derived Drug Candidate, EHP-101, Shows a Unique Mechanism of Action in Systemic Sclerosis Model, Indicating Key Differences Compared to Ajulemic Acid

Biochemical Pharmacology publication describes the unique multi-target mechanism of action of EHP-101 with the potential to be beneficial in systemic sclerosis, a complex disease with no current...
March 12, 2019 08:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals Appoints Lisa Sanford as Chief Financial Officer

SAN DIEGO, CA, March 12, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has appointed Lisa Sanford as...
January 23, 2019 07:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals Appoints Joachim P.H. Schupp, M.D., Dr. med. as Chief Medical Officer

SAN DIEGO, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has appointed Joachim Schupp,...
January 03, 2019 07:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals to Present at the 2nd Annual Sach’s Neuroscience Innovation Forum and the 11th Annual Biotech Showcase 2019

San Diego, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, announced today that CEO, Dr. Jim...
December 18, 2018 11:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals Forms Scientific Advisory Board

Initial appointments include global experts in cannabinoid and drug discovery science SAN DIEGO, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage...
December 04, 2018 07:00 ET | Source: Emerald Health Pharmaceuticals

Emerald Health Pharmaceuticals will Present at the International Cannabinoid-Derived Pharmaceuticals Summit

SAN DIEGO, CA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, today announced that Dr. Jim...